Literature DB >> 8325392

Kinetic properties of pure overproduced Bacillus subtilis phenylalanyl-tRNA synthetase do not favour its in vivo inhibition by ochratoxin A.

A Roth1, G Eriani, G Dirheimer, J Gangloff.   

Abstract

Ochratoxine A (OTA) inhibits growth of Bacillus subtilis at pHs below 7. Since OTA is a phenylalanine analogue, this effect could be due to inhibition of phenylalanine-tRNA synthetase (PheRS) by competition of this mycotoxin with the amino acid. Homogeneous PheRS was purified from Bacillus subtilis and from E. coli transformed with the PheRS gene. The latter produced about 40 times more PheRS than B. subtilis. The Km and Ki values of PheRS, respectively, for phenylalanine and OTA were measured and their concentrations within the cell determined. It appears that the concentration of OTA in the cell, in spite of a 25-fold accumulation, remained too low to significantly compete with phenylalanine. This does not suggest PheRS to be the target of OTA in cell growth and protein synthesis inhibition in Bacillus subtilis. It was also shown that the 2-3-fold increase of PheRS in OTA-treated cells is not due to phenylalanine-controlled attenuation regulation.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8325392     DOI: 10.1016/0014-5793(93)81767-t

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  3 in total

Review 1.  Progress and challenges in aminoacyl-tRNA synthetase-based therapeutics.

Authors:  Christopher S Francklyn; Patrick Mullen
Journal:  J Biol Chem       Date:  2019-01-22       Impact factor: 5.157

2.  Activation markers and cell proliferation as indicators of toxicity: a flow cytometric approach.

Authors:  A Johannisson; A Thuvander; I L Gadhasson
Journal:  Cell Biol Toxicol       Date:  1995-12       Impact factor: 6.691

3.  New class of bacterial phenylalanyl-tRNA synthetase inhibitors with high potency and broad-spectrum activity.

Authors:  Dieter Beyer; Hein-Peter Kroll; Rainer Endermann; Guido Schiffer; Stephan Siegel; Marcus Bauser; Jens Pohlmann; Michael Brands; Karl Ziegelbauer; Dieter Haebich; Christine Eymann; Heike Brötz-Oesterhelt
Journal:  Antimicrob Agents Chemother       Date:  2004-02       Impact factor: 5.191

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.